A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access. Even the most innovative drug is useless if patients…
Puerto Rico leads all US jurisdictions in biopharmaceutical exports, shipping to over 120 countries. With a rapidly expanding life sciences sector and growing pharma logistics capabilities, the island is positioning…
Extending not only lifespan, but “healthspan,” and ensuring people live healthier lives for longer is moving beyond purely clinical settings. Experts gathered last week at the Global Healthspan 2025 Summit…
Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s…
Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease. As people live longer, the threat…
See our Cookie Privacy Policy Here
